SOAT1 and diffuse large B-cell lymphoma: A protein kinase C inhibitor, enzastaurin, that regulates the PI3 K, MAPK and JAK/STAT pathways in vitro, seems to act synergistically with ibrutinib in DLBCL [91,92].